MCM
VNDA icon

MAI Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

MAI Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,651
Closed -$18.3K – 4639
2026
Q1 		$18.3K Buy
2,651
+2,645
+44,083% +$20.4K ﹤0.01% 2846
2025
Q4 		$53 Buy
+6
New +$33 ﹤0.01% 4230

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's VNDA Position: Q2 2026 in Review

MAI Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2026, closing a stake of 2,651 shares — an estimated $18.3K sold.

MAI Capital Management first reported a position in VNDA in Q4 2025 and held it in 2 quarters. The position peaked at $18.3K in Q1 2026. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • MAI Capital Management reported no remaining Vanda Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 2,651 Vanda Pharmaceuticals shares in Q2 2026, an estimated $18.3K.
  • MAI Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • MAI Capital Management's Vanda Pharmaceuticals position peaked at $18.3K in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.